December 12, 2024 – Aphios Awarded NIH SBIR Grant For Development of Anti-CCR5 Nanoparticles to Treat Alzheimer’s Disease
September 24, 2024 – Aphios Corporation Granted Japanese Patent for Novel Compositions to Treat Folic Acid Deficiency and Morning Sickness
May 15, 2024 − Aphios Has Been Granted US Patent For siRNA-Targeted Therapeutics For Treatment Of HIV-1 And Other Diseases.
February 16, 2024- Newsweek Content Creator ‘Investment Reports’ Interviews Dr. Trevor P. Castor on The Future of Aphios and Biotechnology
February 12, 2024 – Dr. Trevor P. Castor Celebrated for Dedication to the Field of Business Management
September 06, 2023-Aphios Awarded NIH Grant for Combination Therapeutic for Chronic Opioid Use Disorder Relapse
June 15, 2023-Aphios APH-1902 Drug Reduces Transplantation Injury and Improves Kidney Transplantation Efficiency
June 01, 2023-Aphios Granted US Patent for Novel, More Potent Bryoid to Treat CNS Diseases and Cancers
May 23, 2023 –Aphios Awarded an NIH Grant to Develop a Double Encapsulated mRNA Vaccine For COVID-19 and Other Diseases
May 22, 2023-Aphios CEO to Chair Roundtable Discussion on Transcytosis-Mediated Brain Delivery At HubXchange
February 01, 2023-Aphios Granted CFI® Trademark for the Pathogen Reduction of Biologics, Human Plasma, Immunoglobulins and Viral Vaccines
July 19, 2022-Aphios to Present its Double-Encapsulated mRNA Vaccine at the 15th Annual Bioprocessing Summit
July 07, 2022 –Aphios Pharma LLC to Host Webinar on The Business Of Cannabis as a Pharmaceutical Medicine
June 21, 2022-Aphios Pharma LLC to Host Webinar on The Science and Technology of Cannabis as a Medicine
May 24, 2022- GBR Interviews Dr. Trevor P. Castor, President & CEO, Aphios Corporation for USA Life Sciences Report
February 08, 2022-Aphios Granted US Patent for Combination HIV Latency Nanoparticles Towards an HIV Cure
July 9, 2021- Biotechnology Brings Microgravity Down to Earth
March 30, 2021 – Aphios Granted US Patent for Novel, More Potent Bryoid to Treat Alzheimer’s diseases, HIV-1 Latency, Prostate Cancer, Glaucoma and Multiple Sclerosis
December 01, 2020 – Aphios Granted US Patent for Combination Therapeutic to Treat Neurodegenerative Diseases
November 18, 2020 – Aphios International Launches Crowdfunding for Groundbreaking CFI Technology for Convalescent Plasma
March 5, 2020 – Aphios Granted Hong Kong Patent for Compound to Treat Neurodegenerative Diseases, Virus Latency, Cancer
January 28, 2020 – Aphios Granted US Patent for Combination HIV Latency Nanotherapeutic Towards an HIV Cure
December 4, 2019 – Aphios Granted US Patent for Oral Administration of Bryostatin-1 Nanoparticles for Treatment of Neurodegenerative Diseases
November 13, 2019 – Aphios Granted US Patent for Vitamin D3 Analog Nanoparticles for the Treatment of Prostate Cancer and Other Diseases
November 6, 2019 – Aphios Developing Pathogen Inactivation Technology for Biologics, Human Plasma, Immunoglobulins, Viral Vaccines
October 15, 2019 – Aphios Granted Chinese Patent For Novel Bryostatin To Treat Alzheimer’s Disease, HIV-I, Cancer
May 13, 2019 – Aphios Granted Japanese Patent For Novel Bryostatins To Treat Alzheimer’s And Other Diseases
March 26, 2019 – Aphios Granted European Patent For Novel Bryostatin to Treat Alzheimer’s Disease, HIV-1, And Cancers
September 26, 2018 – Aphios is Developing Pathogen Inactivation Technology for Human Plasma Units
September 17, 2018 – Aphios Pharma LLC Announces Reg. CF Private Placement Offering
July 06, 2018 – Aphios Pharma LLC to Develop FDA-Approved, Cannabis-Based Drug for Opioid Addiction and other CNS Disorders
June 19, 2018 – Aphios and LSU Health Shreveport Inventors Granted Patent to Improve Transplantation
June 05, 2018 – Aphios Granted United States Patent for Improved Delivery of Targeted siRNA Using Nanotechnology